Table 3.
Overall agreement between MSD and commerical serology assays.
| Assays a | Overall agreement % (95% CI) | Overall agreement % (95% CI) | Overall agreement % (95% CI) |
|---|---|---|---|
| MSD N vs Abbott (N) (n = 316) | 97.5 (97.1–97.9) | 95.7 (94.8–96.6) | 98.2 (97.8–98.6) |
| MSD S vs EUROIMMUN (S) (n = 310) | 92.6 (91.9–93.3) | 90.4 (89.0–91.8) | 93.5 (92.8–94.3) |
| MSD RBD vs EUROIMMUN (S) (n = 310) | 95.2 (94.6–95.7) | 90.4 (89.0–91.8) | 97.2 (96.7–97.7) |
| MSD S vs Siemens (RBD) (n = 301) | 94.0 (93.4–94.6) | 91.8 (90.4–93.1) | 94.9 (94.2–95.6) |
| MSD RBD vs Siemens (RBD) (n = 301) | 96.4 (95.9–96.8) | 90.6 (89.1–92.0) | 98.6 (98.3–99.0) |
a
IgG antibodies detected in the MSD multiplex assay were compared with the results obtained from the commercial serology assays directed against individual antigens.